Blood Loss Kinetics During the First 12 Hours After On-Pump Cardiac Surgical Procedures

The impact of a chest drainage system on retained blood-associated complications after cardiac surgery

OBJECTIVES

Ineffective drainage can lead to retained blood syndrome (RBS), bleeding-associated complications and more postoperative atrial fibrillation (AF). The present study compares outcomes of conventional, active tube clearance (ATC) and portable digital drainage systems after myocardial revascularization.

METHODS

Data from 1222 patients undergoing elective myocardial revascularization with or without a concomitant aortic or mitral valve procedure were considered; data from 1065 patients were retrieved and data from 1049 patients were analysed retrospectively. Patients who received conventional treatment were compared to those treated with ATC and portable digital drainage. Propensity weighting, including comorbidities, medication and perioperative characteristics, was applied for outcome assessment.

RESULTS

In propensity-adjusted patients, 14.6% of conventional patients had interventions for RBS, with 4.1% underdoing early re-exploration for bleeding. In the ATC group, 6.9% required interventions for RBS [odds ratio (OR) 0.43, P < 0.001] with a 3.7% re-exploration rate. Patients in the portable digital drainage group had RBS in 5.1% (OR 0.31, P < 0.001) with a 1.2% rate of re-exploration (OR 0.29, P < 0.001). Postoperative AF dropped by 37% from 29.8% in the conventional to 18.7% in the portable digital drainage cohort (OR 0.31, P < 0.001). In-hospital mortality was similar with 1.6% (6 of 369) in the conventional versus 1.1% (2 of 188) in the ATC versus 0.8% (4 of 492) in the portable digital drainage cohort (P = 0.358).

CONCLUSIONS

Active tube clearance and portable digital drainage cohorts had fewer RBS interventions. In addition, portable digital drainage was associated with reduced early re-exploration for bleeding and lower postoperative AF. Immediately effective chest drainage is crucial to minimize RBS complications postoperatively.

High-Dose TXA Is Associated with Less Blood Loss Than Low-Dose TXA without Increased Complications in Patients with Complex Adult Spinal Deformity

BACKGROUND

Tranexamic acid (TXA) is commonly utilized to reduce blood loss in adult spinal deformity (ASD) surgery. Despite its widespread use, there is a lack of consensus regarding the optimal dosing regimen. The aim of this study was to assess differences in blood loss and complications between high, medium, and low-dose TXA regimens among patients undergoing surgery for complex ASD.

METHODS

A multicenter database was retrospectively analyzed to identify 265 patients with complex ASD. Patients were separated into 3 groups by TXA regimen: (1) low dose (<20-mg/kg loading dose with ≤2-mg/kg/hr maintenance dose), (2) medium dose (20 to 50-mg/kg loading dose with 2 to 5-mg/kg/hr maintenance dose), and (3) high dose (>50-mg/kg loading dose with ≥5-mg/kg/hr maintenance dose). The measured outcomes included blood loss, complications, and red blood cell (RBC) units transfused intraoperatively and perioperatively. The multivariable analysis controlled for TXA dosing regimen, levels fused, operating room time, preoperative hemoglobin, 3-column osteotomy, and posterior interbody fusion.

RESULTS

The cohort was predominantly White (91.3%) and female (69.1%) and had a mean age of 61.6 years. Of the 265 patients, 54 (20.4%) received low-dose, 131 (49.4%) received medium-dose, and 80 (30.2%) received high-dose TXA. The median blood loss was 1,200 mL (interquartile range [IQR], 750 to 2,000). The median RBC units transfused intraoperatively was 1.0 (IQR, 0.0 to 2.0), and the median RBC units transfused perioperatively was 2.0 (IQR, 1.0 to 4.0). Compared with the high-dose group, the low-dose group had increased blood loss (by 513.0 mL; p = 0.022) as well as increased RBC units transfused intraoperatively (by 0.6 units; p < 0.001) and perioperatively (by 0.3 units; p = 0.024). The medium-dose group had increased blood loss (by 491.8 mL; p = 0.006) as well as increased RBC units transfused intraoperatively (by 0.7 units; p < 0.001) and perioperatively (by 0.5 units; p < 0.001) compared with the high-dose group.

CONCLUSIONS

Patients with ASD who received high-dose intraoperative TXA had fewer RBC transfusions intraoperatively, fewer RBC transfusions perioperatively, and less blood loss than those who received low or medium-dose TXA, with no differences in the rates of seizure or thromboembolic complications.

LEVEL OF EVIDENCE

Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

Impact of Additional Administration of von Willebrand Factor Concentrates to Thrombocyte Transfusion in Perioperative Bleeding in Cardiac Surgery

Background

Von Willebrand factor (vWF) is an important part of blood coagulation since it binds platelets to each other and to endothelial cells. In traumatic and surgical haemorrhage, both blood cells and plasmatic factors are consumed, leading to consumption coagulopathy and fluid resuscitation. This often results in large amounts of crystalloids and blood products being infused. Additional administration of vWF complex and platelets might mitigate this problem. We hypothesize that administration of vWF concentrate additionally to platelet concentrates reduces blood loss and the amount of blood products (platelets, red blood cells [RBC], fresh frozen plasma [FFP]) administered.

Methods

We conducted a monocentric 6-year retrospective data analysis of cardiac surgery patients. Included were all patients receiving platelet concentrates within 48 h postoperatively. Patients who additionally received vWF concentrates were allocated to the intervention group and all others to the control group. Groups were compared in mixed regression models correcting for known confounders, based on nearest neighbour propensity score matching. Primary endpoints were loss of blood (day one and two) and amount of needed blood products on day one and two (platelets, RBC, FFP). Secondary endpoints were intensive care unit (ICU) and in-hospital length of stay, ICU and in-hospital mortality, and absolute difference of platelet counts before and after treatment.

Results

Of 497 patients analysed, 168 (34%) received vWF concentrates. 121 patients in both groups were considered for nearest neighbour matching. Patients receiving additional vWF were more likely to receive more blood products (RBC, FFP, platelets) in the first 24 h after surgery and had around 200 mL more blood loss at the same time.

Conclusion

In this retrospective analysis, no benefit in additional administration of vWF to platelet concentrates on perioperative blood loss, transfusion requirement (platelets, RBC, FFP), length of stay, and mortality could be found. These findings should be verified in a prospective randomized controlled clinical trial (www.clinicaltrials.gov identifier NCT04555785).